Skip to main content

CMRX

Stock
Health Care
Biotechnology

Performance overview

CMRX Price
Price Chart

Forward-looking statistics

Beta
2.12
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Company info

SectorHealth Care
IndustryBiotechnology
Employees87
Market cap$83.7M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+11.6
Credit-0.5
Liquidity-5.9
Inflation+7.4
Commodities+5.5
Interest Rates+0.7

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio-8.26
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend day—

News

Top 3 Health Care Stocks That May Crash In Q2

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga (April 7, 2025)
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals

Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.

Zacks Investment Research (March 7, 2025)
Vaccine-maker shares soar on monkeypox outbreak

CNBC's Meg Tirrell joins 'Squawk Box' to break down the companies with vaccines against monkeypox as multiple countries respond to a growing number of cases.

CNBC Television (May 24, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free